Retroperitoneal and Visceral Sarcomas: Issues for the General Surgeon

Author: Woodall Charles E.   Scoggins Charles R.  

Publisher: Southeastern Surgical Congress

ISSN: 0003-1348

Source: The American Surgeon, Vol.73, Iss.6, 2007-06, pp. : 631-635

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Sarcomas represent a rare, heterogeneous group of malignant tumors that arise from the mesenchymal tissues of the body. Although infrequently encountered, these tumors generate vigorous academic interest and an ever-expanding volume of medical literature. Chemotherapy is widely regarded as ineffective because of the often-large tumor burden and lack of good therapeutic drugs. Radiation therapy is often difficult to administer because of locoregional toxicity. Fortunately, targeted immunologic therapies have shown promise in some specific gastrointestinal mesenchymal tumors. To date, sarcoma remains a malignancy best treated operatively. Given the wide heterogeneity and biology of these tumors and the amount of new data available, a review of the current literature is warranted. The first installment of this review series1 dealt with extremity and trunk soft tissue sarcomas; this one will focus on retroperitoneal and visceral sarcomas and the management challenges they pose.